Hookipa Pharma Inc Total Liabilities
Hookipa Pharma Inc total liabilities. Based on the latest financial reports, Hookipa Pharma Inc (HOOK) has total liabilities worth $24.02 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See HOOK cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Hookipa Pharma Inc (2017–2025)
Total liabilities of Hookipa Pharma Inc from 2017 to 2025. This chart illustrates how Hookipa Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Hookipa Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Hookipa Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Intersport Polska S.A.
WAR:IPO
|
Poland | zł210.92 Million |
|
Ecomiam SA
PA:ALECO
|
France | €7.48 Million |
|
Daewoo SBI SPAC 1
KQ:215480
|
Korea | ₩7.64 Billion |
|
Regenbogen AG
F:RGB
|
Germany | €24.18 Million |
|
Energisme
PA:ALNRG
|
France | €13.29 Million |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
USA | $3.04 Million |
|
Minbos Resources Ltd
AU:MNB
|
Australia | AU$2.11 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Hookipa Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hookipa Pharma Inc balance sheet assets.
Liquidity & Leverage Metrics
Hookipa Pharma Inc Total Liabilities Ratios Explained
Hookipa Pharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hookipa Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hookipa Pharma Inc (2017–2025)
The table below shows the annual total liabilities of Hookipa Pharma Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $9.34 Million | -70.19% |
| 2024-12-31 | $31.33 Million | -56.17% |
| 2023-12-31 | $71.48 Million | +5.22% |
| 2022-12-31 | $67.94 Million | +86.37% |
| 2021-12-31 | $36.45 Million | +15.02% |
| 2020-12-31 | $31.69 Million | +22.63% |
| 2019-12-31 | $25.85 Million | +8.36% |
| 2018-12-31 | $23.85 Million | -79.51% |
| 2017-12-31 | $116.39 Million | -- |
About Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancer… Read more